Mikkael A. Sekeres
Expertise in
23
conditions

Dr. Mikkael A. Sekeres

Hematology
1425 Northwest 10th Avenue, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
27 Years of Experience
Expertise in
23
conditions
1425 Northwest 10th Avenue, 
Miami, FL 

Overview

His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML).

Dr. Sekeres is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 438 peer reviewed articles and participating in 5 clinical trials. Dr. Sekeres is currently accepting new patients.

Graduate Institution

University Of Pennsylvania - 1996

Residency

Massachusetts General Hospital, Internal Medicine - 1999

Specialties

Hematology

Licenses

Internal Medicine in FL

Fellowships

Dana-Farber Cancer Institute, Hematology/Oncology - 2002

Hospital Affiliations

Jackson Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

1425 Northwest 10th Avenue, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: February 17, 2026
Intervention Type: Other, Drug
Study Drugs: Azacitidine, Enasidenib
Study Phase: Phase 2
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Drug, Other
Study Drugs: Azacitidine, Lenalidomide, Vorinostat
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Enrollment Status: Suspended
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Luspatercept
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

438 Total Publications

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".
Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".
Journal: Haematologica
Published: April 01, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
1475 Northwest 12th Avenue, 
Miami, FL 
 (0.1 miles away)
305-243-5302
Languages Spoken:
English, Hebrew, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Izidore Lossos is a Hematologist practicing medicine in Miami, Florida. Dr. Lossos is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Transplant. Dr. Lossos is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Moskowitz is a Hematologist practicing medicine in Miami, Florida. Dr. Moskowitz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Non-Hodgkin Lymphoma. Dr. Moskowitz is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Watts is a Hematologist practicing medicine in Miami, Florida. Dr. Watts is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Watts is currently accepting new patients.

Frequently Asked Questions about Dr. Mikkael A. Sekeres

Is Dr. Mikkael A. Sekeres a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mikkael A. Sekeres is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mikkael A. Sekeres specialize in?

While Dr. Mikkael A. Sekeres is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mikkael A. Sekeres participate in research or clinical trials?

Yes. Dr. Mikkael A. Sekeres has published 438 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Mikkael A. Sekeres's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mikkael A. Sekeres accept my insurance?

Dr. Mikkael A. Sekeres accepts most major insurance plans, including Aetna and AvMed. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sekeres's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile